慢阻肺采用噻托溴铵联合舒利迭方案的临床观察及评价

Observation and Clinical Evaluation of Chronic Obstructive Pulmonary Disease with Tiotropium Bromide Combined with Sullidide Treatment

目的:分析慢阻肺采用噻托溴铵联合舒利迭方案的价值。方法:选择2016年1月-2018年1月笔者所在医院收治的160例慢性阻塞性肺部疾病者为研究对象,将其分为两组,每组50例。对照组使用舒利迭治疗,以此为基础,观察组应用噻托溴铵治疗,分析疗效。结果:相较于对照组,观察组受试者治疗效果明显更好(P<0.05)。与对照组相比,观察组受试者干预后MMRC及6MWT分数改善情况更好(P<0.05)。观察组受试者治疗后肺功能改善情况更为显著(P<0.05)。结论:对于慢阻肺患者,使用噻托溴铵联合舒利迭进行治疗,有助于提升患者肺脏功能,可在短时间内消除患者临床症状。安全性强,有效性高,因此值得进一步在临床中推广应用。

Objective:To analyze the value of Tiotropium Bromide combined with Sullidide in chronic obstructive pulmonary disease.Method:A total of 160 patients with chronic obstructive pulmonary disease admitted to our hospital from January 2016 to January 2018 were enrolled in the study.They were divided into two groups of 50 patients each.The control group was treated with Sulidide,and the observation group was treated with Tiotropium Bromide to analyze the therapeutic effect.Result:Compared with the control group,the treatment effect of the observation group was significantly better(P<0.05).Compared with the control group,the observation group had better MMRC and 6MWT scores in the observation group after intervention(P<0.05).In the observation group,the improvement of lung function after treatment was more significant(P<0.05).Conclusion:For patients with COPD,the use of Tiotropium Bromide combined with Suliride can help improve lung function and eliminate clinical symptoms in a short period of time.It is safe and effective,so it is worth further promotion in clinical practice.